The susceptibility of neonates to invasive infection with type III group B streptococci (GBS) in a radioactive antigen-binding assay (RABA)has been correlated with low maternal serum levelsof capsular polysaccharide-specific antibodies. An ELISAwas developedusing capsular polysaccharide covalently coupled to human serum albumin. In sera from 35 healthy women, the range of IgG antibodies to GBS III polysaccharide was 0.05-33.0 p.g1mL, and specificIgA antibodies were 0.08-1.1 p.g1mLj however, no GBS III capsular polysaccharide-specific antibodies of the IgM isotype were detected by the ELISA. The levels of naturally acquired and vaccine-induced antibodies obtained with this ELISA correlated wellwith the results of the RABA(Spearman's rank correlation coefficient, .92). The ELISA has two major advantages over the RABA: It measures specific isotypes and subclasses of antibodies, and it can detect type III polysaccharide-specific antibodies at lower concentrations.
Although the RABA is the standard method by which immunity to GBS is measured, it has two limitations: It does not distinguish among immunoglobulin isotypes or subclasses, and the GBS III RABA is insensitive to levels of antibody < 1 J.Lg/ mL because of a limitation in preparing labeled polysaccharide of sufficiently high specific activity. Other antibody detection systems, including ELISAs, have been used to measure typespecific immunity to GBS. In these immunoassays, antigen is coupled randomly to substances that enhance the adherence of the polysaccharide to plastic surfaces on tubes or ELISA plates [14, [18] [19] [20] [21] [22] [23] . Since the polysaccharide is coupled to these substances by methods that do not precisely define their means of attachment, important epitopes on the antigen could be altered or masked, potentially reducing the specificity and significance of the assay.
We have developed a sensitive and specific ELISA that entails the covalent coupling of GBS III polysaccharide to human serum albumin (HSA) by defined chemical linkages [17] . HSA was chosen because of the low prevalence of human antibodies to this protein [24, 25] ; such antibodies could interfere with the measurement of GBS III-specific immunity. Here we report the results with the new ELISA.
Materials and Methods
Preparation of GBS III antigens and conjugates. Capsular polysaccharide from GBS III strain M781 was isolated and purified [17] . For use as ELISA coating antigens, unconjugated GBS III polysaccharide and GBS III polysaccharide mixed with methylated HSA (supplied by G. M. Carlone, CDC, Atlanta) [26] were compared with GBS III polysaccharide covalently coupled to HSA (Sigma, St. Louis).
For preparation of GBS III polysaccharide HSA conjugates, polysaccharide was first partially oxidized by incubation with 0.01 M sodium periodate in water at 23°C for 90 min in the dark. Ethylene glycol was added to consume any residual periodate; the mixture was dialyzed against water and lyophilized. There is a direct stoichiometric relationship between the amount of periodate added and the number of aldehyde groups formed on C8 of the sialic acid residues of GBS III polysaccharide. This allowed us to introduce aldehyde groups on a defined number of the sialic acid residues of the GBS III polysaccharide and thereby control the number of available coupling sites on the polysaccharide [17] . The degree of oxidation of sialic acid residues was verified by gas chromatography-mass spectrometry (done by H. 1. Jennings, National Research Council of Canada, Ottawa).
GBS III polysaccharide with 15% or 50% oxidized sialic acid residues was coupled to purified HSA (Sigma) by reductive amination as previously described [17] . The protein content of the conjugate was estimated by the Folin-reaction method of Larson et al. [27] ; tetanus toxoid (Amvax, Beltsville, MD) was the standard. The carbohydrate content was assessed by the phenol-sulfuric acid method, with unoxidized GBS III polysaccharide as a standard [28] .
For use in vaccine constructs, monomeric tetanus toxoid (Amvax) was coupled to periodate-treated GBS III polysaccharide as described [17] .
Human sera. Paired sera from 35 healthy volunteers were sampled before and 8 weeks after they received GBS III polysaccharide or polysaccharide-tetanus toxoid conjugate vaccines (15 subjects each) or saline placebo (5 subjects). Naturally acquired GBS IIIspecific antibody was measured in the prevaccination sera. A pool of 5 sera (streptococcal human reference serum [SHRS III]) from persons who had been immunized with GBS III polysaccharidetetanus toxoid conjugate vaccine and had developed high levels ofGBS III-specific antibody (shown by RABA) was used as the standard in the IgG ELISA. The quantity of GBS III-specific antibodies in SHRS III had been determined by quantitative precipitin analysis (see below).
Mouse sera. Outbred CD-1 mice (Charles River Laboratories, Wilmington, MA) were immunized three times at 4-week intervals with 2 Ilg of GBS III polysaccharide conjugated to tetanus toxoid mixed with 5 mg of Al(OH)3 (corresponding to 1.7 mg of AI; Superfos Biosector, Vedbaek, Denmark). Sera were obtained before the first immunization and 2 weeks after the last. All sera were frozen immediately and stored in aliquots at -20°C until use.
RABA. The RABA used was similar to that described by Baker and Kasper [29] as modified by Wessels et al. [30] . In brief, 100 ilL of 3H-labeled GBS III antigen (1000 cpm) was added to 100 ilL of serum diluted in 0.1 M borate-buffered saline with 5% bovine serum albumin, pH 8.3 (Sigma). This preparation was incubated at 37°C for 1 h and subsequently at 4°C for 1 h. Saturated ammonium sulfate (200 ilL) was added to precipitate the globulins, and the suspension was immediately mixed and incubated overnight at 4°C. The mixture was then centrifuged (13,600 g for 3 min; Micro Centrifuge; Fisher Scientific, Pittsburgh), and 150 ilL of the supernatant was transferred to a scintillation vial containing 1.5 mL of distilled H 2 0 and 12 mL of Aquasol-2 (Du Pont/NEN, Boston). A beta liquid scintillation analyzer (Minaxi,BModel 4530; Packard Instrument, Downers Grove, lL) was used for 5-min counts.
All serum specimens were tested in duplicate with an internal standard and a negative control (dilution buffer without serum) in each experiment. The antibody level was calculated as follows: Percentage of antigen bound equals the difference of counts per minute of the negative control minus counts per minute of the test sample divided by counts per minute of the negative control.
A standard curve was generated with SHRS III at several dilutions. There was a linear relationship between the percentage of antigen bound to GBS III -specific antibodies and the logarithm of the antibody concentration when 20%-80% of the radiolabeled antigen was bound. This linearity allowed calculation of the concentration of GBS III-specific antibodies from the percentage of antigen bound. A binding of <20% of antigen in undiluted serum corresponded to a lower limit of detection of 1 Ilg/mL for GBS III-specific antibody.
None of our sera contained hemolyzed red blood cells by visual inspection and by absorbance at 450 nm (A 450 ; Kinetic EL 312E Reader; Bio-Tek Instruments, Winooski, VT). As a control for possible quenching ofthe,B emission of 3H-labeled GBS III polysaccharide by free hemoglobin, hemolyzed human red blood cells (A 45o >3) were added to SHRS III, and the serum was tested by the RABA. Hemolyzed human red blood cells had no influence on the amount of antibody measured in SHRS III.
Quantitative precipitation ofspecific antibody. The amount of type-specific antibody in SHRS III was determined by a modification of the quantitative precipitation method [9, 31] . SHRS III was heat-treated at 56°C for 30 min to destroy complement and delipified by centrifugation (10,000 g, 4°C, 60 min). Serum (3 mL), 1.0% sodium azide (150 ilL), and purified GBS III capsular polysaccharide (50 ilL) were added to plastic tubes (12 X 75 mm with snap caps; Fisher Scientific). The final concentrations of capsular polysaccharide in the four sets of five tubes were 3.12, 6.25, 12.5, and 25 Ilg/mL, respectively. Each tube was rotated at 37°C for 1 h, incubated at 4°C for 10 days, and centrifuged (4122 g, 4°C, 90 min) before the supernatant was carefully decanted and stored at 4°C for further testing. Pellets were washed once by suspension in 3.0 mL of cold 0.9% saline and recovered by centrifugation (4122 g, 4°C, 90 min). The supernatant was discarded and pellets were suspended in 450 ilL of distilled H 2 0 and 500 ilL of 1.0 N NaOH to a final volume of 1.0 mL. The protein content of the washed pellets was determined by the method of Lowry et al. [32] ; human IgG (reagent grade, Sigma) was the standard. This value was taken as the level of precipitating antibodies in SHRS III (y). The level of nonprecipitating antibody in SHRS III was assumed to be represented by the residual radioactive antigen-binding activity measured after quantitative precipitation at equivalence. By comparison of this residual titer with the titer of SHRS III in the RABA before quantitative precipitation, a ratio of nonprecipitating (x) to precipitating (y) antibodies was determined. The total concentration of GBS III-specific antibody in SHRS III was defined as the sum of the precipitable and the residual nonprecipitable antibody levels (x + y).
ELISA. Microtiter plates (lmmulon 4; Dynatech Laboratories, Chantilly, VA) were coated by the addition of 0.1 mL of antigen in 10 mM PBS (pH 7.4) or 0.1 M carbonate buffer with 0.02% azide (pH 9.8) per well. Optimal antigen and conjugate concentrations were determined by checkerboard titration [33] . Plates were individually sealed and incubated for 6 h at 30°C and then washed five times with 10 mMTRlS buffer with 154 mMNaCl and 0.1% JID 1996;173 (January) Brij 35 (Sigma). Sera were diluted in 10 mM PBS with 0.05% Brij 35, 5% newborn calf serum (NCS; Whittaker Bioproducts, Walkersville, MD), and 0.02% azide (i.e., incubation buffer). A O.I-mL volume of the prediluted serum was added to the plates and serially diluted 2-fold in incubation buffer. The plates were then incubated overnight at 4°C, washed as described above, and reincubated with appropriate alkaline phosphatase-conjugated secondary antibody in incubation buffer for 2 h at 30°C. After the wash step, 0.1 mL ofp-nitrophenyl phosphate (l mg/mL phosphatase 104; Sigma) in I MTRIS buffer (pH 9.8) with OJ mMMgCIz was added, and the plates were incubated at 37°C with shaking (Mini Orbital shaker; Belleo Biotech, Vineland, NJ). After 1 h of incubation, the A 405 was determined by kinetic reader (model EL 312E; Bio-Tek Instruments).
The alkaline phosphatase-labeled secondary antibodies used were of high specificity. Specific immunoglobulins (purified human immunoglobulins of different isotypes; Sigma) inhibited binding of their corresponding conjugates to plates coated with the homologous immunoglobulin, whereas purified immunoglobulins of other isotypes gave no inhibition (data not shown).
Quantitation ofIgG and IgA in human sera. For quantitation of human IgG and IgA antibodies, the ELISA plates were coated with the GBS III HSA conjugate at 5 p,g/mL. Alkaline phosphatase-conjugated goat anti-human IgG and anti-human IgA (Biosource International, Camarillo, CA) were diluted 1:3000 and I :2000, respectively. The amount of GBS III-specific IgG antibody in each test serum sample was determined by comparison of the A 405 of the test sample with a standard curve [34, 35] generated with SHRS III. The amount of GBS III-specific IgA antibodies was determined by comparing the A 405 of the test serum sample with a standard curve generated from a separate ELISA that used goat F(ab')2 anti-human IgA (Southern Biotechnology Associates, Birmingham,AL) coated onto microtiter wells and known concentrations ofIgA (reagent grade, Sigma) [34, 35] . The titration curves of the test sera and the immunoglobulin standard were parallel [36] . Results were reported as micrograms of GBS III-specific IgG and IgA antibodies per milliliter. For data expressed as ELISA titers, the titer was defined as the reciprocal dilution of serum giving an absorbance of 1 at 405 urn after incubation for 1 h.
Determination ofIgG subclasses. Type III-specific antibodies of the different IgG subclasses present in human sera were determined as in the total IgG assay but with some modifications. In brief, murine monoclonal antibodies to IgG 1 (clones HP-6001 and HP-6069), IgG2 (clones HP-6002 and HP-6014), IgG3 (clone HP-6050), and IgG4 (clone HP-6023) were used as secondary antibodies (Hybridoma Reagent Laboratory, Kingsville, MD; Sigma) and alkaline phosphatase-conjugated goat anti-mouse IgG at a dilution of 1:2000 was used as conjugate (Southern Biotechnology). The anti-human IgG subclass antibodies were used at a concentration that gave identical adsorption at 405 urn when they were used as antigen and goat anti-mouse IgG was used as conjugate. The start dilution of serum was 1:50. Secondary antibodies were incubated overnight at room temperature, and conjugate was incubated for 3 h at 30°C. The results are reported as titers that are the reciprocal dilution of sera that gave an absorbance of 1.0 at 405 urn.
Determination ofIgM titer. The GBS III HSA conjugate was used at 5 p,g/mL as the ELISA plate-coating antigen for determination of mouse IgM antibody and at 0.2 p,g/mL for determination of human IgM antibody. In these assays, alkaline phosphataseconjugated goat anti-human IgM (Biosource International) and goat anti-mouse IgM (Southern Biotechnology) were used at a dilution of 1:2000. The antibody titers were reported as the reciprocal dilution of serum that gave an absorbance of 1.0 at 405 urn after incubation for 1 h.
Quantitation of mouse IgG and IgG subclasses. The IgG and IgG subclasses of specific antibodies to GBS III capsular polysaccharide in mouse serum were determined in the ELISA with the GBS III HSA conjugate at 5 p,g/mL. Alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotechnology) diluted I :2000 and alkaline phosphatase-conjugated goat anti-mouse IgGl, IgG2a, IgG2b, and IgG3 (Southern Biotechnology) were diluted I: 1000. The levels of antibodies in various sera was determined by comparing the A 405 of the test serum with a standard curve generated from a separate ELISA that used anti-mouse IgG (Fab-specific; Sigma) coated onto microtiter wells and known concentrations of IgG (Sigma) or IgG subclass standards (Southern Biotechnology) [34, 35] . The titration curves of the test sera and the immunoglobulin standards were parallel [36] . Results were reported as micrograms of specific antibody (total IgG or an IgG subclass) per milliliter.
Inhibition ELISA. Competitive inhibition of binding of sera to GBS III HSA-conjugate-coated ELISA plates were done as described above except that sera were mixed with various inhibiting antigens at concentrations from 0.5 ng/mL to 10 p,g/mL. All sera used in the competitive inhibition ELISAs were diluted to Controls. Controls for each assay included a known reference serum containing antibody to GBS III (IS III) and an antibodynegative serum.
Statistics. Nonparametric statistics were used with InStat 2.0 software (Graphpad Software, San Diego). Spearman's rank correlation coefficient was used to determine the correlation between GBS III-specific antibodies measured by RABA and those measured by ELISA.
Results
Binding of GBS III polysaccharide to ELISA plates. GBS III polysaccharide alone or mixed with methylated HSA did not bind well to ELISA plates; antibody titers were <3000 in severalsera, includingSHRS III, which had high levels of GBS III-specific antibodies measured in the RABA. The SHRS III titer was increased to 1:56,000 when the coating antigen was the GBS III polysaccharide covalently conjugated to HSA. Therefore, this antigen was used for all subsequent experiments. The GBS III HSA ELISA gave identical titers for sera with natural and vaccine-induced antibodies when differently constructed conjugates were used as the coating antigen (15% or 50% oxidized sialic acid residues) and when conjugates were prepared in different batches (data not shown).
Four human sera without antibodiesto GBS III polysaccharide detectable in the RABA were used to estimate nonspecific binding to the ELISA plates. Both a detergent (Brij) and a protein (NCS) were needed in the incubation buffer to block nonspecific binding. In addition,pyrogen-free water (McGhee, Irvine, CA) was used in all buffers, and this reduced the background A 405 reading in these 4 sera at a 1:100 dilution from a mean of 0.690 to 0.053 [38, 39] .
ELISA specificity. Competitive inhibitionwas doneto evaluate the antigenic specificity of IgG, IgM, and IgA antibodies to GBS III. SHRS III or other human sera with specific GBS III antibodies were mixed with various inhibiting antigens at concentrations from 0.5 ng/mL to 10 J.lg/mL and tested in the isotype-specific ELISAs. The ELISA coating antigen (GBS III HSA conjugate), the homologous and all heterologous GBS capsularpolysaccharides, GBS group B-specific carbohydrate, HSA, and pneumococcal type 14 polysaccharide (which is similar to GBS III polysaccharide but lacks the sialic acid residue) [40, 41] were tested as inhibitors. The ELISA was specific for .
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.1 1 10 Conen. of Inhibitor (J.lg/ml) detection limit for human GBS III IgA was 80 ng/mL with a 1:200 dilution of test serum (figure 2B).
Correlation between GBS III-specific antibodies measured by RABAand ELISA. For the 35 paired sera, Spearman's rank correlation coefficient for the correlation between the levels of specific GBS III antibodies measured by the RABA and the sum of specific GBS III IgA and IgG antibodies measured by ELISA was .92 (P < .001; figure 3) . The relationship between the antibody concentrations measured in the RABA and those measured in quantitative precipitation assays was not linear at concentrations of antibody < 1 j1g/mL,whereas the quantitative relationship between precipitin results and ELISA measurements was linear to 0.25 ng/mL. Figure 4 shows the levels of antibodies to GBS III polysaccharide measured by ELISA and RABA in preimmunization sera from 35 volunteers. The majority of these sera had levels of specific antibodies below the limit of detection in the GBS III RABA. None of the 35 sera had specific IgG antibodies to GBS III below the detection limit of the IgG ELISA, and only 4 of the 35 had specific anti-type III IgA antibodies below the detection limit of the IgA ELISA.
The GBS III polysaccharide-specific IgG antibodies in SHRS III were predominantly of the IgG2 subclass (lgG2 titer, 11,000). GBS III-specific antibodies of the IgGl, Igm, and IgG4 subclasses were detected minimally with titers of 100, <50, and <50, respectively.
Type III IgM response. None of the 35 preimmunization sera contained GBS III polysaccharide-specific IgM antibodies. The secondary antibody for the human IgM assay was highly specific for IgM and could detect purified human IgM (reagent grade, Sigma) at a concentration as low as 400 pg/mL. Only 3 serum samples from volunteers after immunization with GBS III polysaccharide-containing vaccines had GBS III-specific IgM responses. All 3 also had markedly increased IgG levels. IgM titers in the sera from these 3 vaccinees was 200-1096.
Sera from the 3 volunteers with vaccine-induced increases in GBS III IgM antibodies were completely inhibited from binding to GBS III HSA-coated plates by the GBS III polysaccharide and the GBS III HSA conjugate. The concentration of GBS III polysaccharide, unconjugated or conjugated to HSA, which inhibited 50% of the binding of IgM antibodies in 1 of these sera, was 1-2 ng/mL polysaccharide (figure lC). HSA at concentrations from 0.5 ng/mL to 10 j1g/mL did not inhibit binding of GBS III IgM antibodies.
To test whether the overall poor IgM responses in GBS vaccinees were a result of inhibition of the binding of GBS IIIspecific IgM antibodies by competitive binding of specific IgG antibodies, another competitive inhibition ELISA was done. A postvaccination serum sample with high GBS III-specific IgM antibody titer was incubated on GBS III HSA-coated plates with dilutions of SHRS III at concentrations of 0.005-100 ng of specific GBS III IgG antibodies. Specific GBS III IgG at the concentrations tested did not inhibit binding of GBS III-specific IgM antibodies in the GBS III-HSA ELISA. antibodies of different isotypes reacting with GBS III polysaccharide (figure 1). Some cross-reaction was seen for GBS type la in the GBS III IgM ELISA; however, the concentration of GBS type la needed to inhibit binding of 50% of the serum was 500-fold higher than that ofGBS III polysaccharide (figure lC). Of particular importance was that the polysaccharidewhether unconjugated or conjugated to HSA-inhibited to the same extent the binding of GBS III capsular polysaccharidespecific antibodies to the GBS III HSA conjugate-coated plates. Some populations of antibodies in human sera react with shared epitopes on the GBS III polysaccharide and the type 14 pneumococcal polysaccharide [30, 40, 42] . In the IgG ELISA, 100-fold less inhibition was seen with the type 14 polysaccharide than with the GBS III polysaccharide (figure lA). To ensure that the ELISA was detecting these known cross-reactive antibodies rather than specific pneumococcal type 14 antibodies, paired sera from four high-level responders to the pneumococcal type 14 polysaccharide vaccine were tested in the GBS III ELISA for antibody rises (sera supplied by P. Anderson, University ofRochester, NY) [43] . No significant increases in GBS III-specific antibodies were evident in these sera. 1000. , . . . ------------------ Several laboratories have developed assays for the measurement of antibodies to GBS type-specific polysaccharides [9, 14, [18] [19] [20] [21] [22] [23] . Although most of these laboratories agree that immunity to GBS infection correlates with the transplacental transfer to the neonate of maternal IgG antibodies to the capsular polysaccharide of the infecting strain [9, 14, 15, 20] , there is disagreement on the absolute level and isotype of antibodies present in similar study populations [9, [18] [19] [20] 44] .
Sensitivity ofthe ELISA.
The RABA, the assay most often used to measure natural and vaccine-induced anticapsular antibodies [9, 40, 45, 46] , does not distinguish among immunoglobulin isotypes. However, the GBS III RABA shows a good correlation between levels of naturally acquired (r = .7) and vaccine-induced (r = .949) antibodies to GBS III polysaccharide in paired maternal and cord sera [9, 45] ; this observation implies that the majority of naturally acquired antibodies are of the IgG isotype.
Another problem with the GBS III RABA is its insensitivity. The sensitivity of RABA depends on specific activity of the radiolabeled polysaccharide. Specific activity of GBS III poly- 10 100
All other sera tested (before and after vaccination) had A 40 S readings of ,,;;0.5 at a 1:100 dilution. IgM-specific binding to the plate by 4 sera with A 40 S values of 0.5 was not inhibited by the GBS III polysaccharide, the GBS III HSA conjugate, HSA alone, or the type la polysaccharide at concentrations from 0.5 ng/mL to 10 p,g/mL.
2-mercaptoethanol reduction of sera. Type III -specific antibodies of IgA, IgG, and IgM isotypes in sera treated with 2-mercaptoethanol or with buffer alone were measured in ELISA. 2-mercaptoethanol reduction of pre-and postvaccination sera had no influence on GBS III-specific IgG antibodies. The amounts of detectable IgA antibodies specific for GBS III was reduced 40%~50% after 2-mercaptoethanol treatment. GBS III -specific IgM titers were eradicated in the 3 sera with vaccine-induced GBS III IgM response. The A 40S of all 5 sera with noninhibitable GBS III IgM response was reduced from an OD of ,,;;0.5 to ,,;;0.1 at a 1:50 dilution after 2-mercaptoethanol treatment.
Utility ofELISA for the detection ofmouse antibodies. We tested the ability of plates coated with the GBS III HSA conjugate to detect GBS III -specific antibodies in mouse serum. The antigenic specificity of the mouse ELISA was similar to that documented in human serum (above) for all isotypes and subclasses tested. (The specificity of the IgG subclass ELISA is shown in figure 5 .) GBS III capsular polysaccharide, whether alone or conjugated to HSA, inhibited to the same extent the binding of specific antibodies to plates coated with the GBS III HSA conjugate. The detection limit of the assay for mouse saccharide extrinsically labeled with 3H is -20 cpm/ng of polysaccharide. Our GBS III RABA does not measure antibody concentrations < 1 /-lg/mL. Since the median IgG level detected by the modified ELISA reported here was 0.41 /-lg/mL, the enhanced sensitivity of the ELISA represents a significant improvement in the measurement of natural immunity.
Unfortunately, GBS polysaccharides do not adhere well directly to ELISA plates. Investigators have sought methods of enhancing adherence to plastic plates, primarily through the attachment of the polysaccharides to proteins. Methods of increasing the adherence of GBS polysaccharides to ELISA plates have included random coupling to proteins (or in one case tyramine [18, 47, 48] ) through hydroxyl groups on the polysaccharide and with the use of either cyanogen bromide [14, 18, 19, 47, 48] or biotinylation [22, 23] .
The most common method couples polysaccharide to poly-L-lysine and uses cyanuric chloride for "activation" [20, 21] . The actual bonding is covalent with the spacer between f. amino groups on poly-L-lysine and carboxylate groups on the polysaccharide's sialic acid residues. This carboxylate group is critical to the conformational epitope of the polysaccharide towards which protective antibodies are directed [49] . It has not been demonstrated whether this coupling method interferes with the expression of this important epitope, thereby distorting the quantitation of protective immunity. It is likely that the conformational epitope would be altered if a large number of sialic acid residues were coupled.
In studies with the polysaccharides of groups A and C meningococci, Arakere and Frasch [26] ionically bound polysaccharide to methylated HSA for the coating of ELISA plates. In our hands, methylated HSA did not enhance the binding of GBS III polysaccharide to ELISA plates (data not shown).
We have used a coupling method to make GBS conjugate vaccines in which periodate oxidation of the polysaccharides results in the formation of an aldehyde at C8 of a controlled number of sialic acid residues [17] . This aldehyde has been used for direct coupling to lysine groups on carrier proteins by reductive amination [17, 50] . HSA was the carrier protein chosen for use in this ELISA because of its adequate number of f. amino groups and its minimal reactivity with antibodies in human serum [24, 25] . We previously showed that this coupling method results in a definable and reproducible covalent linkage that does not alter the important conformational epitopes on the GBS polysaccharides [17] .
Most methods for the measurement of antibodies have provided evidence that the protective maternal IgG crosses the placenta to the neonate. There is some disagreement concerning the role of naturally acquired 19M antibodies. Anthony and colleagues [18, 47] , who conducted studies with a tyraminated polysaccharide, reported that naturally occurring antibodies were mainly of the IgM class (median, 1.33 j.lg/mL) and not IgG (median, 0.13 j.lg/mL). This preponderance of IgM was supported by Boyer et al. [19] , who reported a median of 5.4 j.lg/mL of IgM in pregnant women and 0.06 j.lg/mL of IgG. Both of these observations are discrepant with the RABA data that indicate a good correlation of naturally occurring antibody levels in paired maternal and cord sera [9, 11, 29, 44] .
We could not detect specific IgM in the 35 serum samples we obtained from volunteers before immunization. Our inability to detect IgM was not due to inhibition of binding of specific GBS III IgM antibodies in the GBS III IgM ELISA by higher affinity and more abundant GBS III IgG antibodies. All naturally occurring GBS antibodies were of either the IgG or the IgA isotype. We found a measurable IgM signal by ELISA that was abolished after 2-mercaptoethanol treatment. However, this signal was not inhibited by GBS III capsular polysaccharide or by HSA, indicating that the IgM signal in the prevaccination sera represents nonspecific binding of immunoglobulins of the 19M isotype. Only 3 of 30 sera tested showed specific and inhibitable IgM responses after immunization with GBS III polysaccharide-containing vaccines.
The levels of antibodies measured by the ELISA described here correlated very well with the quantitative results of the GBS III RABA (r = .92). The correlation of these two assays indicates that they can be used interchangeably to measure GBS III antibodies in the same sera. The GBS III ELISA has four advantages over the GBS III RABA: It distinguishes specific antibodies of each isotype and subclass; it is more sensitive than our RABA, detecting IgG concentrations as low as 50 ng/mL and IgA concentrations as low as 80 ng/mL at a serum dilution of 1:200; it uses smaller amounts of serum than the RABA and thus is particularly useful for studies of specimens from neonates; and it does not use radioisotopes. In light ofthese advantages, we believe that this ELISA is a useful addition to current assays for the measurement of antibodies to GBS polysaccharides.
